Adaptin Bio, Inc. focuses on developing innovative therapies that harness the power of the immune system to treat various diseases, particularly cancer and autoimmune disorders. The company employs a proprietary platform that enables the design and optimization of biologic therapies, including monoclonal antibodies and fusion proteins. This platform is built on a deep understanding of protein engineering and the interactions between immune cells and target antigens, allowing for the creation of highly specific and effective therapeutic candidates.

In addition to its core therapeutic development efforts, Adaptin Bio is advancing its pipeline through collaborations and partnerships that enhance its research capabilities. The company is committed to leveraging cutting-edge technologies in immunology and molecular biology to identify and validate novel targets, ultimately aiming to deliver transformative treatments to patients. Their approach emphasizes a rigorous scientific foundation, ensuring that each product in their pipeline is backed by robust preclinical and clinical data.

United States

Adaptin Bio, is a pioneering biotechnology company dedicated to revolutionizing drug delivery. Our focus is on developing innovative technologies that enhance how medications and other therapeutic compounds reach their target destinations within the body.

Our core mission is to overcome a major hurdle in medicine: ensuring effective delivery of drugs to specific tissues.

Adaptin Bio, Inc.

Company Details